PET scan study for PD-L1 in certain cancers
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial tests a new PET imaging agent, [18F]AlF-NOTA-PCP2, to detect PD-L1 protein in tumors. It may help guide treatment decisions for people with glioblastoma, head and neck, lung, or esophageal cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed cancer diagnosis: glioblastoma, head and neck squamous cell, non-small cell lung, or esophageal cancer.
- You are 18 years or older.
- Your tumor has been tested and shows PD-L1 protein.
- You have at least one tumor that can be seen on scans.
- You are in good enough health to do daily activities (ECOG score 0-1).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of PET scan that uses a special tracer to find lung tumors. The goal is to see if this scan can better detect cancer cells, which may help doctors plan the best treatment for you.
This trial uses a special PET/CT scan that targets a protein on some cancer cells to help detect and evaluate malignant tumors. It may help doctors better map tumors before any cancer treatment starts.
This study uses a PET scan with a special radioactive tracer (68Ga-DOTA-Siglec-9) to look at cancer in certain people. It may help doctors better see cancer-related activity and guide treatment planning for selected cancers.
This trial uses a special PET scan called 68Ga-NK224 to look for a protein called PD-L1 in tumors. This may help doctors understand your cancer better and find the right treatment for you.
This trial tests a new type of imaging scan (PD-L1 PET/CT) that may help doctors better see and understand cancers. The scan uses a special tracer to highlight cancer cells in your body, which could help guide treatment decisions.
This trial tests a special injection (a radioactive tracer) that lights up PD-L1 in your tumors during a PET scan. It helps doctors see which tumors might respond to immunotherapy.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.